Patheon Appoints Andrew G. Long as Senior Vice President and Global Business Controller

DURHAM, N.C. — February 8, 2016 – Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, has hired Andrew G. Long as senior vice president and global business controller. Long will report to Stuart Grant, chief financial officer for Patheon, and will be based at the company's headquarters in Durham, N.C.

Long will focus on Patheon's financial planning and performance management tools and processes, in support of the company's position as a category leader in the pharma services industry.

He brings more than 25 years of experience to Patheon. He most recently served as vice president, global finance of the Fisher Scientific Group for Thermo Fisher Scientific, a biotechnology product development company, where he was responsible for global financial planning and analysis, controllership, mergers and acquisitions and strategic planning.

"Andy is a great addition to our organization, said Grant. "He is a seasoned professional with vast experience in all aspects of finance. We will benefit from his experience as we advance our business strategy."

Prior to joining Thermo Fisher, Long was vice president, worldwide finance and supply chain management at Cambrex Corporation, responsible for global financial planning, reporting and analysis for a division with 14 manufacturing and distribution sites across 10 countries. Previously, Long served in a number of roles of increasing responsibility for companies including Eaton Corporation, Emerson Electric and Abbott Laboratories.

"I am very pleased to join Patheon," said Long. "The company is widely recognized as a market leader with a solid growth profile."
Long holds a Bachelor of Science from Indiana University and a Master of Business Administration from the Kellogg Graduate School of Business, Northwestern University.

About Patheon
Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

###

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.